However, like the data shown in a review article (33) and other studies (6, 34, 35), we predict that sensitivity is likely to decrease when more-diverse specimens resistant to AMK or CAP are tested. For KAN, the sensitivity was only 85%, which could be increased by testing the eis promoter, mutations in which have been shown to account for nearly 20% of KAN resistance in global clinical isolates (33).